PMID- 11311659
OWN - NLM
STAT- MEDLINE
DCOM- 20010913
LR  - 20191104
IS  - 1040-8428 (Print)
IS  - 1040-8428 (Linking)
VI  - 38
IP  - 2
DP  - 2001 May
TI  - New therapeutic modalities in the treatment of graft-versus-host disease.
PG  - 129-38
AB  - Acute and chronic GvHD are still a major concern in allogeneic hematopoietic stem 
      cell transplantation, still contributing substantially to morbidity and mortality 
      in this therapeutic procedure. Over the past decade, many advances have been made 
      with regard to the prevention and treatment of GvHD using various drugs such as 
      cyclosporine A, FK506, mycophenolate mofetil and/or monoclonal IL-2 receptor 
      antagonists. Despite these measurements with regard to the prevention of acute 
      GvHD, it is very difficult to treat these clinical conditions successfully. 
      However, if patients do not experience any GvHD often the desired effect of graft 
      versus leukemia (GvL) remains absent increasing the probability of a relapse, in 
      particular, in patients transplanted, which are considered at higher risk for 
      relapse. At the present time, new strategies in the prevention of acute GvHD are 
      in progress in particular the use of genetic manipulated donor T cells expressing 
      suicide genes. Further clinical and laboratory studies are required in order to 
      improve the prevention and, in particular, the therapy of established GvHD.
FAU - Basara, N
AU  - Basara N
AD  - Clinic of Bone Marrow Transplantation and Haematology/Oncology, Dr Ottmar-Kohler 
      Str. 2, 55743, Idar Oberstein, Germany. office@bmt-center-io.com
FAU - Kiehl, M G
AU  - Kiehl MG
FAU - Fauser, A A
AU  - Fauser AA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
SB  - IM
MH  - Combined Modality Therapy
MH  - Graft vs Host Disease/diagnosis/epidemiology/*therapy
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Severity of Illness Index
RF  - 84
EDAT- 2001/04/20 10:00
MHDA- 2001/09/14 10:01
CRDT- 2001/04/20 10:00
PHST- 2001/04/20 10:00 [pubmed]
PHST- 2001/09/14 10:01 [medline]
PHST- 2001/04/20 10:00 [entrez]
AID - S1040-8428(00)00123-2 [pii]
AID - 10.1016/s1040-8428(00)00123-2 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2001 May;38(2):129-38. doi: 
      10.1016/s1040-8428(00)00123-2.